Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...
Tags: Sunesis Pharmaceuticals, Medicine
The European Commission (EC) has granted orphan drug designation to Sunesis Pharmaceuticals' Vosaroxin drug. Vosaroxin is a first-in-class anti-cancer quinolone derivative, (AQD), used for the treatment of acute myeloid leukemia (AML). ...
Tags: vosaroxin, AQD, AML, anti-cancer quinolone derivative